{'fraction_non_alphanumeric': 0.021696252465483234, 'fraction_numerical': 0.013806706114398421, 'mean_word_length': 5.430379746835443, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Sequencing treatment for metastatic prostate cancer

In the past 10 years there have been significant advances in the understanding and treatment of metastatic prostate cancer. These include the earlier use of docetaxel chemotherapy, and the use of abiraterone, enzalutamide, radium‐223 and cabazitaxel.1–6 This has led to significant improvements in survival, but has increased the choice and complexity of treatment. In this article, the authors review these advances and look at the sequencing of agents.